Design of purine nucleoside phosphorylase inhibitors. 1986

J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks

Purine nucleoside phosphorylase inhibitors hold promise as specific immunosuppressive, anti-T cell leukemic, and antiuricopoietic agents. The best inhibitors available that are biologically active have Ki values from 10(-6) to 10(-7) M and fall into two categories: noncleavable nucleosides preferably iodinated at the C-5' position and C-8-substituted guanine or acycloguanosines. More potent inhibition is shown by phosphorylated acyclonucleosides that function as multisubstrate analogs, but these compounds are excluded from cells. The X-ray analysis of the human erythrocytic enzyme is beginning to reveal the nature of the active site and to explain the structure-activity relationships that have been established with analog substrates and inhibitors.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010430 Pentosyltransferases Enzymes of the transferase class that catalyze the transfer of a pentose group from one compound to another.
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011683 Purine-Nucleoside Phosphorylase An enzyme that catalyzes the reaction between a purine nucleoside and orthophosphate to form a free purine plus ribose-5-phosphate. EC 2.4.2.1. Inosine Phosphorylase,Nicotinamide Riboside Phosphorylase,Purine Nucleoside Phosphorylases,Nucleoside Phosphorylases, Purine,Phosphorylase, Inosine,Phosphorylase, Nicotinamide Riboside,Phosphorylase, Purine-Nucleoside,Phosphorylases, Purine Nucleoside,Purine Nucleoside Phosphorylase,Riboside Phosphorylase, Nicotinamide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014961 X-Ray Diffraction The scattering of x-rays by matter, especially crystals, with accompanying variation in intensity due to interference effects. Analysis of the crystal structure of materials is performed by passing x-rays through them and registering the diffraction image of the rays (CRYSTALLOGRAPHY, X-RAY). (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Xray Diffraction,Diffraction, X-Ray,Diffraction, Xray,Diffractions, X-Ray,Diffractions, Xray,X Ray Diffraction,X-Ray Diffractions,Xray Diffractions

Related Publications

J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
July 1995, Acta crystallographica. Section D, Biological crystallography,
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
February 1993, Farmaco (Societa chimica italiana : 1989),
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
January 2011, Biomeditsinskaia khimiia,
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
February 1990, The Journal of biological chemistry,
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
July 1994, Journal of medicinal chemistry,
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
November 2005, Acta crystallographica. Section D, Biological crystallography,
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
June 1991, Biochemical pharmacology,
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
June 1994, Drug design and discovery,
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
August 1991, Biochemistry,
J D Stoeckler, and S E Ealick, and C E Bugg, and R E Parks
January 2013, Biomeditsinskaia khimiia,
Copied contents to your clipboard!